Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA +1.69%94 Return-on-Tangible-Asset is 7.45% as of Mar. 2026, which is 49% below its 10-year median of 14.51. GuruFocus rates NSE:BETA with a GF Score™ of 94/100 and a GF Value™ of ₹1,991.23 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Beta Drugs ranks better than 53.27% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Beta Drugs's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹362 Mil. Beta Drugs's average total tangible assets for the quarter that ended in Mar. 2026 was ₹4,859 Mil. Therefore, Beta Drugs's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.45%.
The historical rank and industry rank for Beta Drugs's Return-on-Tangible-Asset or its related term are showing as below:
NSE:BETA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.79 Med: 14.51 Max: 22.23
Current: 3.79
During the past 13 years, Beta Drugs's highest Return-on-Tangible-Asset was 22.23%. The lowest was 3.79%. And the median was 14.51%.
NSE:BETA's Return-on-Tangible-Asset is ranked better than 53.27% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.14
vs NSE:BETA: 3.79
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Beta Drugs Return-on-Tangible-Asset Related Terms
Beta Drugs Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BETA vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.45% mean?
Beta Drugs (NSE:BETA) has a Return-on-Tangible-Asset of 7.45% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Beta Drugs and its competitors. This is 49% below median its historical median of 14.51. Over the past decade, Beta Drugs' Return-on-Tangible-Asset has ranged from 3.79 to 22.23. According to the industry distribution chart, Beta Drugs ranks #471 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 46.7%.
Is Beta Drugs' Return-on-Tangible-Asset too high?
Beta Drugs' current Return-on-Tangible-Asset of 7.45% is 49% below median its 10-year median of 14.51. Over the past 10 years, this metric has ranged from a low of 3.79 to a high of 22.23. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.14. Beta Drugs' value of 7.45% is 137.3% above this industry median. Based on the distribution chart, Beta Drugs ranks #471 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beta Drugs has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #471 out of 1008 companies for Return-on-Tangible-Asset. This puts Beta Drugs in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.14. Beta Drugs' value of 7.45% is 137.3% above this benchmark. Historically, Beta Drugs' own Return-on-Tangible-Asset has ranged from 3.79 to 22.23 over the past decade. While the company's 10-year median is 14.51 vs. the industry median of 3.14, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.14, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Return-on-Tangible-Asset of 7.45% is 137.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Return-on-Tangible-Asset is 7.45%, which is 49% below median its own 10-year median of 14.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,991.23, compared to a current price of ₹2,315.60 — trading 16.3% above its estimated fair value. The current Return-on-Tangible-Asset is 7.45%, which is 49% below median its 10-year median of 14.51 and 137.3% above the Drug Manufacturers industry median of 3.14. Beta Drugs' overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Return-on-Tangible-Asset is 7.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,315.60 is trading 16.3% above its estimated GF Value™ of ₹1,991.23.
GuruFocus considers Beta Drugs to be Modestly Overvalued.
Key valuation signals for NSE:BETA:
Return-on-Tangible-Asset: 7.45% (49% below median its 10-year median of 14.51)
GF Value™: ₹1,991.23 vs. price of ₹2,315.60 (16.3% above fair value)
Industry Position: 137.3% above the Drug Manufacturers median (#471 of 1008)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
94GF Score
Get the complete analysis for NSE:BETA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
